- Eli Lilly plans to invest $3 billion to build a new oral medicine manufacturing facility in Katwijk, the Netherlands.
- The project will create 500 permanent jobs and around 1,500 construction jobs, reinforcing Lilly’s global manufacturing network.
Eli Lilly and Company has announced plans to construct a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. The facility will expand Lilly’s global capacity to produce oral medicines and strengthen its supply chain network.
The site will feature advanced manufacturing technologies such as dock-to-dock automation, paperless production, process analytical technology, and spray-dried dispersion to enhance the bioavailability of oral medicines. It will also support the production of orforglipron, Lilly’s first oral small molecule GLP-1 receptor agonist, which the company expects to submit for global regulatory approval for obesity by the end of this year.
“With extensive investments already underway in the U.S., our planned expansion in Europe further strengthens our ability to deliver medicines to patients worldwide. Leiden Bio Science Park offers access to a skilled workforce, reliable infrastructure, and proven pharmaceutical manufacturing capabilities.”
David A. Ricks, Lilly chair and CEO.
The new facility is expected to create 500 high-skilled jobs and 1,500 construction roles during the build phase, which is anticipated to begin next year, pending final government permits and approvals.
Lilly currently operates manufacturing sites across France, Ireland, Italy, and Spain, and has announced additional new facilities in Ireland, Germany, and the Netherlands. The company said this latest investment reflects its commitment to supporting the European life sciences ecosystem and advancing its sustainability goals, including carbon-neutral operations and zero waste to landfills.
